References
- Kawasaki T, Kosaki F, Osawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974; 54: 271–6
- Leung D YM. Kawasaki disease. Curr Opin Rheumatol 1993; 5: 41–50
- Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: Clinical analyses in 195 cases. J Pediatr 1986; 108: 923–7
- Suzuki A, Kamiya T, Kuwahara N, et al. Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1,100 cases. Pediatr Cardiol 1986; 7: 3–9
- Leung D YM, Geha RS, Newburger JW, et al. Two monokines, interleukin-1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J Exp Med 1986; 164: 1958–72
- Terai M, Kohno Y, Niwa K, Toba T, Sakurai N, Nakajima H. Imbalance among T-cell subsets in patients with coronary arterial aneurysms in Kawasaki disease. Am J Cardiol 1987; 60: 555–9
- Leung D YM, Burns JC, Newburger JW, Geha RS. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 1987; 79: 468–72
- Furukawa S, Matsubara T, Jujoh K, et al. Peripheral blood monocyte/macrophage and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol 1988; 48: 247–51
- Maury C PJ, Salo E, Pelkonen P. Circulating interleukin-1 beta in patients with Kawasaki disease. N Engl J Med 1988; 319: 1670–1
- Lang BA, Silverman ED, Laxer RM, Lau AS. Spontaneous tumor necrosis factor production in Kawasaki disease. J Pediatr 1989; 115: 939–43
- Leung D YM, Cotran RS, Kurt-Jones E, Burns JC, Newburger JW, Pober JS. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1989; 2: 1298–302
- Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor and gamma interferon in Kawasaki disease. Clin Immunol Immunopathol 1990; 56: 29–36
- Terai M, Kohno Y, Namba M, et al. Class II major histocompatibility antigen expression on coronary arterial endothelium in a patient with Kawasaki disease. Hum Pathol 1990; 21: 231–4
- Moncada S, Palmer R MJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109–42
- Ketteler M, Border WA, Noble NA. Cytokines and L-arginine in renal injury and repair. Am J Physiol 1994; 267: F197–207
- de Belder AJ, Radomski MW, Martin JF, Moncada S. Nitric oxide and the pathogenesis of heart muscle disease. Eur J Clin Invest 1995; 25: 1–8
- Nagashima M, Matsushima M, Matsuoka H, Ogawa A, Okumura N. High-dose gammaglobulin therapy for Kawasaki disease. J Pediatr 1987; 110: 710–12
- Newberger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633–9
- Wennmalm Å, Benthin G, Edlund A, et al. Metabolism and excretion of nitric oxide in humans: an experimental and clinical study. Circ Res 1993; 73: 1121–7
- Trachtman H, Gauthier B, Frank R, Futterweit S, Goldstein A, Tomczak J. Increased urinary nitrite excretion in children with minimal change nephrotic syndrome. J Pediatr 1996; 128: 173–6
- Bank N, Aynedjian HS. Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int 1993; 43: 1306–12
- Tsukahara H, Miura M, Tsuchida S, et al. Effect of nitric oxide synthase inhibitors on bone metabolism in growing rats. Am J Physiol 1996; 270: E840–5
- Aeberhard EE, Henderson SA, Arabolos NS, et al. Nonsteroidal anti-inflammatory drugs inhibit expression of the inducible nitric oxide synthase gene. Biochem Biophys Res Commun 1995; 208: 1053–9
- Amin AR, Vyas P, Attur M, et al. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc Natl Acad Sci USA 1995; 92: 7926–30